Blueprint Medicines saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 78 to 81.
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Blueprint Medicines is building a consolidation with a 121.90 entry. See if the stock can break out in heavy trade.
Blueprint Medicines posted 0% earnings growth last quarter. Revenue gains came in at 127%.
Blueprint Medicines holds the No. 55 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
